Medici List crest
Disclaimer: This is a simplified summary of a public company filing. See full disclaimer here.

ABBOTT LABORATORIES

CIK: 18001 Annual ReportLatest: 2026-02-20

10-K / February 20, 2026

Abbott Laboratories

Overview

Abbott Laboratories is a global healthcare company organized into four reportable segments:

  • Established Pharmaceutical Products
  • Diagnostic Products
  • Nutritional Products
  • Medical Devices

The company discovers, develops, manufactures, and sells a broad, diversified line of healthcare products across these segments.

Acquisition activity

  • On November 19, 2025, Abbott entered into a definitive agreement to acquire Exact Sciences Corporation to enter the cancer diagnostics market.
  • The acquisition is subject to closing conditions, including Exact Sciences shareholder approval and regulatory clearances.
  • Abbott plans to fund the acquisition with approximately $20 billion of borrowings and would incur additional indebtedness.

Global footprint and scale

  • Employees: approximately 115,000 as of December 31, 2025; about 69% of employees are outside the United States.
  • Manufacturing and facilities: 89 manufacturing facilities globally.
    • Medical Devices: 33 sites
    • Diagnostic Products: 21 sites
    • Established Pharmaceutical Products: 22 sites
    • Nutritional Products: 13 sites
  • Real estate: owned/leased properties totaling about 44 million square feet; approximately 65% of this property is owned by Abbott. Abbott’s principal corporate offices are located in Illinois and are owned by the company.

Geographic mix

  • In 2025, approximately 61% of Abbott’s net sales were outside the United States (roughly 39% U.S., 61% international).

Financial snapshot

  • Consolidated indebtedness: approximately $12.9 billion as of December 31, 2025.
  • Planned acquisition financing: approximately $20 billion of borrowings for the Exact Sciences acquisition.
  • Abbott noted potential impacts on credit ratings and financing flexibility from higher indebtedness.

Segment-level product and market descriptions

Established Pharmaceutical Products

  • Broad line of branded generic pharmaceuticals with worldwide manufacturing and sales outside the U.S.
  • Key therapy areas and example products:
    • Gastroenterology: Creon, Duspatal, Dicetel, Heptral, Transmetil, Samyr, Duphalac
    • Women’s health: Duphaston, Femoston
    • Cardiovascular/metabolic: Lipanthyl, TriCor, Omacor, Physiotens, Synthroid
    • Pain/CNS: Serc, Brufen, Sevedol
    • Respiratory/vaccines: Clarithromycin (Klacid/Claribid/Klaricid), Influvac vaccine
    • Biologic products including oncology, immunology, and women’s health biosimilars

Diagnostic Products

  • Diagnostic systems and tests marketed globally.
  • Major product families:
    • Core laboratory and transfusion medicine systems: Alinity family, ARCHITECT, Cell-Dyn
    • Molecular diagnostics: Alinity m, m2000; Vysis FISH lines
    • Point-of-care systems: i-STAT, i-STAT Alinity, cartridges
    • Rapid diagnostics: BinaxNOW, Panbio, ID NOW
    • Cardiometabolic testing: Afinion, Cholestech LDX
    • Toxicology testing
    • Informatics and automation: Track, AlinIQ, Indexor, RALS

Nutritional Products

  • Pediatric and adult nutritional products.
  • Infant formulas and follow-ons: Similac and multiple Similac variants
  • Adult and specialty nutrition: Ensure, Glucerna, PediaSure, Pedialyte
  • Healthcare-enteral nutrition for institutions: Jevity, Osmolite, Nepro

Medical Devices

  • Devices across cardiovascular, electrophysiology, vascular, structural heart, diabetes care, and neuromodulation.
  • Examples:
    • Rhythm management: Assurity MRI, Endurity MRI pacemakers; Aveir leadless pacemakers; Ellipse, Fortify, Gallant ICDs; implantable monitors (Confirm Rx, Jot Dx)
    • Electrophysiology: TactiFlex and TactiCath ablation catheters; EnSite mapping systems; Agilis NxT introducers; ViewFlex intracardiac echocardiography
    • Heart failure and monitoring: HeartMate LVADs, CardioMEMS HF System, CentriMag
    • Vascular and structural heart: XIENCE drug-eluting stents; various stents and closure devices; MitraClip, Navitor valve; surgical valve systems
    • Diabetes care and CGM: FreeStyle and Libre CGM systems (sensors, test strips, accessories)
    • Neuromodulation: Proclaim spinal cord stimulation systems, Proclaim DRG, Infinity and Liberta RC DBS systems
    • A broad range of coronary, peripheral, and vascular therapy devices

Customers and market positioning

  • Abbott markets brands to consumers, pharmacists, physicians, other healthcare providers, and government agencies.
  • The company competes on technology, price, convenience, service, product performance, and long-term cost-effectiveness.